In a study examining the effects of DPP4 and/or SGLT2 inhibitors in the early and advanced phases of diabetes in db/db mice, the authors observed that the combination of DPP4 and SGLT2 inhibitors exerted greater beneficial effects on β-cell mass and function, especially in the early phase of diabetes rather than an advanced phase [27]. The gene discussed is DPP4; the disease is diabetes mellitus.